Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.49 |
| ▸ | CNR1 | P21554 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22340783 | 0.81 | TSHR (0.70) | CNR2CNR1TSHRLMNAMAPT | |
| SCHEMBL8909807 | 0.81 | ACHE (0.46) | CNR2CNR1TSHRMEN1OPRM1 | |
| SCHEMBL11319163 | 0.79 | CNR2 (0.44) | CNR2CNR1TSHRLMNAMAPT | |
| SCHEMBL20870842 | 0.79 | CNR2 (0.57) | CNR2CNR1TSHRLMNAMAPT | |
| SCHEMBL22340711 | 0.78 | TSHR (0.70) | CNR2CNR1TSHRLMNAMAPT | |
| SCHEMBL6538841 | 0.77 | TDP1 (0.45) | MAPTMEN1ALDH1A1CYP3A4SLC6A4 | |
| Nitrogen SCHEMBL11740757 | 0.77 | TSHR (0.64) | CNR2CNR1TSHRLMNAMAPT | |
| SCHEMBL50190 | 0.76 | ALDH1A1 (0.43) | CNR2TSHRMAPTALDH1A1CYP1A2 | |
| SCHEMBL22340648 | 0.76 | CNR2 (0.59) | CNR2CNR1TSHRMAPTKMT2A | |
| SCHEMBL26694572 | 0.75 | LTA4H (0.57) | CNR2CNR1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034959-B2 | Methods of treating cancer with an antibody-drug conjugate | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-7977465-B2 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-RE41252-E1 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090209734-A1 | PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR | MEDAREX, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | MEDAREX, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7507420-B2 | Peptidyl prodrugs and linkers and stabilizers useful therefor | MEDAREX, INC. (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | PDIA5, CD38, DUT | CNR2 3060/4885CNR1 2993/4885TSHR 3420/4885 |
| US-20090209734-A1 | PEPTIDYL PRODRUGS AND LINKERS AND STABILIZERS USEFUL THEREFOR | VIP, PIN1, PDF | CNR2 3405/4885CNR1 3109/4885TSHR 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.